基于真实世界分析肾性贫血住院患者使用人促红素治疗的现状

目的:基于真实世界分析我院肾性贫血住院患者使用人促红素注射液治疗的现状,为更好规范我院肾性贫血治疗药物的使用。方法:使用我院病历系统(HIS系统)和检验系统数据,回顾性调查我院肾内科在2023年1月-12月期间使用人促红素注射液的肾性贫血住院患者124例,分析其在真实世界的使用情况。结果:124例患者中,男性64例,女性60例,透析患者104例,未行透析患者20例,平均年龄为(68.65±12.47)岁;平均住院天数为(9.77±6.04)天;平均合并疾病种数为(7.73±1.81)种。用药不合理率为46.77%(58/124),主要表现为给药次数过少、感染未控制、未透析且Hb≥90 g/L等。结论:人促红素注射液治疗肾性贫血时存在较多不合理现象,需要多部门共同协作,加强其合理用药的管理,共同保障肾性贫血患者用药的安全性和有效性。

OBJECTIVETo better standardize the use of drugs for the treatment of renal anemia in our hospital,so to analyze the recombinant human erythropoietin injection in hospitalized patients with renal anemia in our hospital based on real-world.METHODSUsing data from HIS system and laboratory system of our hospital,base on real-world to analyzed124 inpatients with renal anemia who were treated with recombinant human erythropoietin in the nephrology department of our hospital from January to December 2023 were retrospectively investigated.RESULTSThe 124 patients included 64 males and 60 females,104 dialysis patients and 20 non-dialysis patients,with an average age of(68.65±12.47)years.The average LOS was(9.77±6.04)days.The average number of diseases was(7.73±1.81).The irrational rate of drug use was 46.77%(58/124),and the main manifestations were too few times of administration,uncontrolled infection,no dialysis and Hb≥90 g/L and so an.CONCLUSIONThere are many unreasonable phenomena in the treatment of recombinant human erythropoietin.So it is necessary to cooperate with multiple departments to strengthen the management of rational drug use,and jointly ensure the safety and effectiveness of drug use in patients with renal anemia.